Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Current Treatment Options in Oncology

• Publication date

  2019-03-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11864-019-0634-5PMID 30923913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study

  2019cited by this paper
• Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

  2019cited by this paper
• Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study

  2018cited by this paper
• Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

  2018cited by this paper
• Understanding the tumor immune microenvironment (TIME) for effective therapy

  2018cited by this paper
• Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

  2018cited by this paper
• Recurrent Glioblastoma Treated with Recombinant Poliovirus

  2018cited by this paper
• Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

  2018cited by this paper
• Advances in the use of PARP inhibitor therapy for breast cancer

  2018cited by this paper
• Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma

  2018cited by this paper
• Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

  2018cited by this paper
• Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

  2018cited by this paper
• Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

  2018cited by this paper
• Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

  2018cited by this paper
• Abstract PD6-10: KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1–positive, previously untreated, metastatic triple-negative breast cancer (mTNBC)

  2018cited by this paper
• Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)

  2018cited by this paper
• Abstract PD5-01: Final results of NeoMONARCH: A phase 2 neoadjuvant study of abemaciclib in postmenopausal women with hormone receptor positive (HR+), HER2 negative breast cancer (BC)

  2018cited by this paper
• A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC).

  2018cited by this paper
• Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.

  2018cited by this paper
• Immune profiling of BRCA-mutated breast cancers.

  2018cited by this paper
• Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.

  2018cited by this paper
• Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer

  2018cited by this paper
• Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.

  2018cited by this paper
• Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).

  2017cited by this paper
• The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?

  2017cited by this paper
• Rationale for stimulator of interferon genes-targeted cancer immunotherapy.

  2017cited by this paper
• CDK4/6 inhibition triggers anti-tumor immunity

  2017cited by this paper
• Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.

  2017cited by this paper
• Breast cancer

  2017cited by this paper
• Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer

  2017cited by this paper
• A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

  2017cited by this paper
• Cancer statistics, 2017

  2017cited by this paper
• Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs

  2017cited by this paper
• Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.

  2017cited by this paper
• Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.

  2017cited by this paper
• Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

  2017cited by this paper
• Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

  2017cited by this paper
• World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015.

  2016cited by this paper
• A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

  2016cited by this paper
• Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy

  2016cited by this paper
• Current clinical trials testing the combination of immunotherapy with radiotherapy

  2016cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, Gene-Dense, and Active Chromatin Regions.

  2015cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

  2014cited by this paper
• ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

  2014cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

  2013cited by this paper
• Pertuzumab

  2012cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Triple-negative breast cancer: an unmet medical need.

  2011cited by this paper
• Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

  2009cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

  1992cited by this paper

• Efficacy and safety of immunotherapy combined with chemotherapy in both neoadjuvant and adjuvant settings among triple-negative breast cancer: A meta-analysis of randomized clinical trials.

  2025cites this paper
• Ursolic acid affects autophagy and apoptosis of breast cancer through PLK1 via AKT/mTOR signaling pathway

  2025cites this paper
• The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer

  2024cites this paper
• Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.

  2024cites this paper
• Enhancing AI Research for Breast Cancer: A Comprehensive Review of Tumor-Infiltrating Lymphocyte Datasets

  2024cites this paper
• Granzyme B Expression in the Tumor Microenvironment as a Prognostic Biomarker for Patients with Triple-Negative Breast Cancer

  2023cites this paper
• Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer

  2023cites this paper
• New Frontiers in the Role of Locoregional Therapies in Breast Cancer: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel.

  2023cites this paper
• Immunotherapy and immunobiomarker in breast cancer: current practice and future perspectives.

  2022cites this paper
• Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes

  2022cites this paper
• Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer

  2022cites this paper
• Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity

  2022cites this paper
• Frequency of Expression of PD-1 and PD-L1 In Head And Neck Squamous Cell Carcinoma And their Association With Nodal Metastasis: A Cross-Sectional Study

  2022cites this paper
• A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs

  2022cites this paper
• Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer

  2021cites this paper
• Structure-Indicated LC-MS/MS Bioanalysis of Therapeutic Antibodies.

  2021cites this paper
• Multiplex spatial systems analysis of local nanodose drug responses predicts effective treatment combinations of immunotherapies and targeted agents in mammary carcinoma

  2021cites this paper
• The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.

  2021cites this paper
• HLA AND CANCER

  2021cites this paper
• Система HLA и рак

  2021cites this paper
• Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

  2021cites this paper
• TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer

  2021cites this paper
• Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

  2021cites this paper
• The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.

  2021cites this paper
• CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer

  2021cites this paper
• MHC Class I Loss in Triple-negative Breast Cancer

  2021cites this paper
• Multimodal Bone Metastasis-associated Epidermal Growth Factor Receptor Imaging in an Orthotopic Rat Model.

  2021cites this paper
• Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.

  2020cites this paper
• Atezolizumab for the treatment of breast cancer

  2020cites this paper
• Targeting claudin‐4 enhances chemosensitivity in breast cancer

  2020cites this paper
• An Overview of Vasculogenic Mimicry in Breast Cancer

  2020cites this paper
• CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models

  2020cites this paper
• In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with 89Zr-labeled avelumab.

  2020cites this paper
• A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer

  2020cites this paper
• Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer

  2020cites this paper
• Prostate immunology: A challenging puzzle.

  2020cites this paper
• Clinical Data on Immunotherapy in Breast Cancer

  2020cites this paper
• Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution

  2020cites this paper
• RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity

  2020cites this paper
• Rechallenge of anti-PD-1/PD-L1 antibody showed a good response to metastatic breast cancer: a case report.

  2020cites this paper
• Targeting claudin-4 enhances chemosensitivity of triple negative breast cancer

  2019cites this paper
• PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells

  2019cites this paper
• Preventive CTLA-4-Ig Treatment Reduces Hepatic Egg Load and Hepatic Fibrosis in Schistosoma mansoni-Infected Mice

  2019cites this paper
• The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies.

  2019cites this paper
• The Promise of Immunotherapy for Breast Cancer Brain Metastases

  2019cites this paper
• Tn antigen analogues: the synthetic way to "upgrade" an attracting tumour associated carbohydrate antigen (TACA).

  2019cites this paper
• Recent Advances in Nuclear Imaging of Receptor Expression to Guide Targeted Therapies in Breast Cancer

  2019influential citation
• PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer

  2019cites this paper
• Insights into breast cancer phenotying through molecular omics approaches and therapy response

  2019cites this paper
• Clinical application of the developed device for wound closure after radical mastectomy

  2019cites this paper